Lifeboat Foundation

Countries must join forces to avert a global food crisis from COVID-19.

In every hospital labor and delivery department, a resource nurse decides which patients go to which room, which nurses care for which patients, and much more. “It’s a lot to keep in your head,” says Kristen Jerrier, a resource nurse in the labor and delivery department at Beth Israel Deaconess Medical Center in Boston.

Glucose metabolism plays a key role in the cytokine storm seen in influenza, and the link could have potential implications for novel coronavirus infections.

The Pentagon’s cutting edge science department is working to create a therapeutic “shield” that could be mass produced to provide temporary protection for people from diseases like the coronavirus, boosting their immunity until an actual vaccine is developed. The result could also help slow the viruses’ advance, buying time for hard-pressed hospitals and clinics worldwide.

The Defense Advanced Research Projects Agency, or DARPA, has funded efforts to create such therapies from studying COVID-19 samples from individuals who have already recovered from the virus. Scientists working with the organization’s Pandemic Prevention Platform (PPP) are sequencing the B cells of one individual who recovered from COVID-19. B cells create antibodies, proteins created by the human immune system to fight a particular invading microorganism.

A new technology aims to make tumors their own worst enemy in the fight against cancer — and Stanford Medicine will be the first in the world to incorporate the treatment into the clinic.

The first generation of a machine using this technology — the X1, from the company RefleXion Medical — harnesses positron emission tomography to deliver radiation that tracks a tumor in real time. This PET feedback allows the system to send beams of radiation to destroy cancerous cells with heightened precision.

Researchers hope that this “biology-guided radiotherapy” will increase accuracy, safety and efficacy of cancer radiation treatment. Stanford physicians plan to test the X1 later this year through clinical trials at Stanford Hospital. Their first step will be to obtain approval by the Food and Drug Administration.

On March 16, Moderna and the National Institute of Allergy & Infectious Diseases (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.

Without placing too much significance on this, it is a good sign, suggesting that the trial is progressing well and there are no obvious bad side effects from the first round.

Lisa Jackson, senior investigator, Kaiser Permanente Washington Health Research Institute, who is heading the study, told USA Today that the physicians at Kaiser Permanente’s Vaccine Treatment and Evaluation Unit in Seattle don’t have results from the first round. This suggests that the study data is blinded, meaning it will not be released until a specific point in the trial.

Researchers have developed a way to modify an existing cancer drug with toxic side effects into something that is less toxic to blood platelets and more effective at removing harmful and inflammatory senescent cells, one of the reasons we age, from mice.

What are senescent cells?

As you age, increasing numbers of your cells enter into a state known as senescence. Senescent cells do not divide or support the tissues of which they are part; instead, they emit a range of potentially harmful chemical signals that encourage nearby healthy cells to enter the same senescent state. Their presence causes many problems: they reduce tissue repair, increase chronic inflammation, and can even eventually raise the risk of cancer and other age-related diseases.

Researchers investigating cribellate spiders have discovered a unique comb structure that could help inform future equipment used to manipulate nanofibers. Nanofibers have been hard to handle in a lab setting as they can stick to the equipment attempting to manipulate them, but a new study published in the journal ACS Applied Nanomaterials reveals how spiders can help us to create non-stick tools for such scenarios.

Cribellate spiders are so named because of their unique web-spinning anatomy. Most spiders have a long single spinneret that they use to produce a single thread, whereas cribellate spiders have a silk-spinning organ. This organ acts like a plate with lots of small, ever so slightly raised protrusions, each of which produces a very fine silk just a few nanometers thick. The spiders then comb these thin fibers out using a calamistrum structure on their legs, producing silk with a woolly texture. This woolly-textured silk entraps the spider’s prey, but somehow, they are able to handle it without getting caught up in their own webs.

Nanofibers are a hot area of research right now but one of the difficulties in their handling is that they commonly stick to the equipment trying to manipulate them. Lead author Anna-Christin Joel, from RWTH Aachen University, and her colleagues wondered if the solution to this frustrating problem could be found within the silk-immune spiders’ anatomy.

Circa 2017

Abilify MyCite raises new privacy concerns.